Navigation Links
Labopharm Reports Results for First Quarter Fiscal 2008
Date:5/8/2008

ith the early stages of product launches. Labopharm believes that the penetration of markets in which its product has already been launched, as well as additional product launches globally, will result in continued annual growth in product sales.

Conference Call

Labopharm will host a conference call today (Thursday, May 8, 2008 at 8:30 a.m. ET) to discuss its first quarter fiscal 2008 results. To access the conference call by telephone, dial 416-644-3428 or 1-800-731-5774. Please connect approximately five minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Thursday, May 15, 2008 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21270272 followed by the number sign. A live audio webcast of the conference call will be available at http://www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's curre
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...OLUMBIA, S.C., Nov. 21 ...ittee for Quality Assurance (NCQA) ranked BlueChoi...d of America,s Best Health Plans(TM), published in..., , The respected annual ranking ranks the n...y, member satisfaction and NCQA accreditation scor...
(Date:11/21/2008)...ONTVALE, N.J., Nov. 21 B...ounced that its shareholders overwhelmingly approv... acquisition of Barr by Teva Pharmaceuticals Indus... vote demonstrated the overwhelming support of the... L. Downey, Barr,s Chairman and CEO. "We are pleas...
(Date:11/21/2008)... In 430 B.C., a new and deadly diseaseits cause re... city-state was teeming with citizens, soldiers an...nd Sparta. As streets filled with corpses, social ...llness returned twice and Athens lost a third of i...Athens marked the beginning of the end of the Gold...
(Date:11/21/2008)...EW ROCHELLE, N.Y., Nov. 21 A prest...lthcare providers will gather in Williamsburg, VA ...learn practical, clinical information on cutting-e...ures, and innovative research advances that impact...ation, and registration information is available a...
Breaking Medicine News(10 mins):Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4Health News:17th Annual Congress on Women's Health Convenes March 27-29, 2009 in Williamsburg, VA 2
...are itself free from bird flu, incidence of which ...stry hard, Agriculture Minister Sharad Pawar said ...aries and directors of Animal Husbandary on Avian ...to implement the central package for poultry farme...
...rong evidence that clusters of leukemia and other ...ation.// ‘Comare’, Committee on Medical Aspects o... advise ministers on the effect of radiation expos...hood cancer from 1969 to 1993. The researchers sug...
... covers everything from checkups, prescription dru...operations was approved unanimously// by the San F...irst health care plans which offer adults to gain ...f their immigration or employment status. The pla...
...ataka, Andhra Pradesh, Tamil Nadu and Maharashtra ...s to stop the rapid spread of Chikungunya.// The d...d lakhs of people in the biggest occurrence after ...54-55. Andhra Pradesh Health Minister K. Rosaiah ...
Other Medicine News:Health News:Study Links Children Living In Isolated Rural Areas With A Higher Risk Of Cancer 2
(Date:11/20/2008)...IA, Nov. 20 GlaxoSmithKli...States Food and Drug Administration (FDA) granted ... for the treatment of thrombocytopenia in patients... purpura (ITP) who have had an insufficient respon...omy. The approval is a significant milestone for P...
(Date:11/20/2008)... 20 Arpida (SWX:,ARPN) ...sory Committee of the,U.S. Food and Drug Administ...al of intravenous iclaprim, an antibiotic currentl...th complicated skin and skin structure infections,...esistant Staphylococcus,aureus (MRSA). , A...
(Date:11/20/2008)...swire-FirstCall/ -- Bionovo, Inc.,(Nasdaq: BNVI... the Phase 1B,clinical trial of their lead drug c...ZL101, at the Society for Integrative Oncology,s F.... The Company,s oral presentation was selected,a...a part of the Best of the,SIO Session on November...
(Date:11/20/2008)...ire/ -- Radius Health ("Radius") announced today t... second institutional financing round, increasing ... total amount raised since the company,s inception...estors participated in the financing, led by MPM B..., The Wellcome Trust, HealthCare Ventures, Oxford ...
Breaking Medicine Technology:FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2SAFC Pharma to Increase Viral Product Manufacturing Capacity 2583 1SAFC Pharma to Increase Viral Product Manufacturing Capacity 2583 2SAFC Pharma to Increase Viral Product Manufacturing Capacity 2583 3AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement 2580 1AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement 2580 2AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement 2580 3Black Americans Still Wary of Clinical Trials 9519 1Black Americans Still Wary of Clinical Trials 9519 2Black Americans Still Wary of Clinical Trials 9519 3Black Americans Still Wary of Clinical Trials 9519 4Cholesterol Drug Zetia Doesnt Cut Heart Attack Risk 3A Study 9516 1Cholesterol Drug Zetia Doesnt Cut Heart Attack Risk 3A Study 9516 2Cholesterol Drug Zetia Doesnt Cut Heart Attack Risk 3A Study 9516 3
...ccine could offer protection,for infants against ...isease , , TORONTO, Canada, May 11, , 2007 ...rom a,Phase II vaccine clinical study presented th... (PAS) Annual Meeting in,Toronto, Canada. The new ... vaccine holds potential to protect infants in the...
...SINESS WIRE)--May 14, 2007 - BioDelivery,Sciences ...ional,statistically significant results with BEMA ... in its Phase III efficacy clinical,trial for the ...inuing analysis of the,secondary efficacy endpoint... SPID 15 (Summary of Pain Intensity Difference at,...
Other Medicine Technology:GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets,Phase II Study Endpoints of Immunogenicity and Safety Compared to,Licensed Vaccines 2GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets,Phase II Study Endpoints of Immunogenicity and Safety Compared to,Licensed Vaccines 3GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets,Phase II Study Endpoints of Immunogenicity and Safety Compared to,Licensed Vaccines 4GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets,Phase II Study Endpoints of Immunogenicity and Safety Compared to,Licensed Vaccines 5BDSI Announces Positive Key Secondary Efficacy Endpoint Results for,Bema Fentanyl 2BDSI Announces Positive Key Secondary Efficacy Endpoint Results for,Bema Fentanyl 3BDSI Announces Positive Key Secondary Efficacy Endpoint Results for,Bema Fentanyl 4
...iol (E2) is the most potent, naturally secreted es...vary [1]. In the ovary, estradiol is produced from...nt estrogen derived from androstenedione. Estrone ...ues. In men, small amounts of estradiol are produc...
Innotrac Aio! 2nd generation cardiac troponin I assay is a highly sensitive immunoassay providing quantitative results directly from whole blood in less than 18 minutes. The assay is based on a uniqu
...TROS ECi brings true automation and continuous ran...g. Highly sensitive assays for thyroid, anemia, ca...one metabolism testing are currently available, wi...e VITROS ECi can simultaneously process 60 accessi...
...TE 2500 is a high-throughput immunoassay system bu...IMMULITE 2000 with the important addition of Logic... assays to be designed for optimal performance wit...llows for critical assays such as the cardiac biom...
Medicine Products: